Search results
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Benzinga via Yahoo Finance· 7 hours agoOn Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed...
1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer
Motley Fool via Yahoo Finance· 16 hours agoThis figure is about to explode higher due to positive results from the Crown study. On May 31, ...
Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data
Reuters via AOL· 5 days agoPfizer said it expects its cancer drug Lorbrena to top $1 billion in annual sales by 2030 on the...
What To Know About Personalized mRNA Cancer Vaccines After Promising Trials From Moderna And Merck
Forbes· 20 hours agoMerck and Moderna released “extremely impressive” positive data from a mid-stage trial of the...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Morningstar· 1 day agoPfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman ...
FDA approves Moderna’s mRNA RSV vaccine for older adults
CNN via Yahoo News· 4 days agoThe US Food and Drug Administration has approved another vaccine that can help protect older people...
NHS launches personalised mRNA cancer vaccines trial
Clinical Trials Arena via Yahoo Finance· 5 days agoThe NHS has commenced a clinical trial offering personalised cancer vaccines being developed by BioNTech and Genentech to patients. The first patient was...
Pfizer says its its lung cancer drug Lorbrena could be a $1 billion blockbuster
Quartz· 4 days agoOn Friday, at the American Society of Clinical Oncology meeting in Chicago, Pfizer released...
The Push to Get More People Into Long COVID Studies
Medscape· 20 hours agoSince then, it's been a tough road for Spier, 37, who said he wouldn't wish his hellish condition on anyone. Last spring, he enrolled in a clinical trial
The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for...
Morningstar· 15 hours agoThe Company has found that its lead nanoviricide broad-spectrum antiviral drug candidate NV-387, when given as a slow bolus intravenous infusion, resulted in a relatively flat plateau of blood ...